Moderna’s adapted COVID-19 vaccine that targets Omicron XBB.1.5 approved by MHRA

An adapted COVID-19 vaccine from Moderna (Spikevax) that targets the Omicron XBB 1.5 subvariant, has today been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.

More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer

MADRID — Patients with advanced endometrial cancer had less disease progression and lived longer when they received the immune checkpoint inhibitor (ICI) atezolizumab (Tecentriq) in

October 24, 2023

First-Ever Pig Kidney Transplant Performed in Living Recipient

A 62-year-old man with end-stage kidney disease (ESKD) received the world’s first successful transplant of a genetically edited pig kidney, doctors in Boston announced. The

March 22, 2024

Senators Mull Ways to Stop Patent ‘Abuse’ by Pharma Companies

Senators and experts on Tuesday examined the range of tools that brand-name drug manufacturers have used to keep generic and biosimilar competition at bay —

May 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.